Get comprehensive updates on ongoing clinical trials across biotech, medtech, and pharma. Learn about groundbreaking studies and research findings that are setting the stage for future FDA approvals and new treatments.
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
The gene therapy space just got a massive validation with uniQure’s AMT-130 delivering unprecedented results in Huntington’s disease. Three-year data showing approximately 75% slowdown in
Microbiome subsidiary faces workforce reduction following ulcerative colitis study setback, highlighting development risks in emerging therapeutic area Vedanta Biosciences, PureTech Health’s microbiome-focused subsidiary, announced workforce
Allogeneic CAR-T leader advances multiple trials with $302.6M cash position, diversifying beyond oncology into autoimmune applications Allogene Therapeutics reported strong financial positioning with $302.6 million
Neurodegeneration specialist achieves over 50% enrollment in Phase 1b PRECISE-AD trial ProMIS Neurosciences announced significant progress in its 128-patient Phase 1b PRECISE-AD trial for Alzheimer’s
Cancer therapeutics company extends MIRACLE trial footprint with $7.6M cash runway through Q4 2025 Moleculin Biotech reported $7.6 million in cash on hand, expected to
Canadian biotech advances RESOLVE Phase 2b trial for gastrointestinal indications with topline data expected H2 2026 Eupraxia Pharmaceuticals announced Q2 results and achieved a significant
First-ever Phase 3 study in HPV16-positive head and neck cancer demonstrates strong enrollment progress PDS Biotech reported Q2 results alongside significant progress in its groundbreaking
Melanoma vaccine combination shows numerical benefit but misses primary endpoint, shares plummet 34% IO Biotech’s Phase 3 trial evaluating its IO102/IO103 therapeutic cancer vaccine (Cylembio)
